Issue 57

Has psychedelic research reached a tipping point?

In 2021, psychedelic medicines moved from the frontiers of scientific research to the front pages of newspapers worldwide.

This was driven by a growing body of research and the results of groundbreaking clinical trials. Studies have demonstrated the potential for psychedelic medicines to treat a wide range of illnesses, where currently available treatments have proven ineffective, which has garnered the support of healthcare providers, patients and the public.

The Psychedelics as Medicine Report: Third Edition revealed two-thirds of Europeans and North Americans support the legalisation of psychedelic-assisted therapy, with jurisdictions enacting legislation to facilitate its adoption. Six states in the United States have decriminalised psychedelic medicines, with 20 loosening regulations to support research into their efficacy.

Read More

PSYCHEDELICS CAN CHANGE HUMANITY FOR THE BETTER

Rick Doblin, Founder of MAPS, outlined the potential of psychedelic healthcare for The Guardian.

Read More

SEELOS THERAPEUTICS RAISES US$20M IN PRIVATE PLACEMENT

The company plans to use the funds to develop ketamine treatments for central nervous system disorders.

Read More

BUSINESS AND INVESTMENT

Quarterly financial results from Novamind, Braxia, Red Light Holland and Wesana.

Clairvoyant closes C$3m funding round.

atai increases ownership stake in COMPASS.

Novamind partners with Bienstar Wellness to create Latin American clinic network.

Seelos licenses drug delivery technology to iX Biopharma for US$9m.

Numinus develops psilocybe mushroom screening.

Psychedelic telemedicine has arrived. What could possibly go wrong?

Numinus develops psilocybe mushroom screening.

The promise and pitfalls of psychedelics.

Entheon provides update on DMT clinical trials.

Novel psychedelic treatment approach bypasses hallucinogenic effects.

Telescope acquires rights to UBC’s psilocybin research and patents.

MYND receives Canadian government grant for neuroinflammation research.

Magic mushrooms and start-up spiritualism.

PsyBio files manufacturing patent applications.

PharmaTher secures Japanese patent for ketamine formulation.

Awakn appoints Kate Butler as CFO.

SCIENCE AND RESEARCH

Is psychedelic research funding starting to shift?

The rise of psychedelic retreats.

Psilocybin reduces relapse for those with alcohol use disorder.

Academic centres start to take psychedelics seriously.

Psychedelic drugs can treat mental illness.

Are psychedelics an effective treatment for mood disorders?

Psychedelics may have long-term impact treating depression.

MindMed and Liechti publish data on psilocybin and SSRI interaction.

The Psychedelics as Medicine Report: Third Edition was powered by Blossom, the psychedelic industry’s largest database of market intelligence.

Blossom supports the development of the sector by providing data on companies, their research and clinical trials, empowering operators and policymakers to make informed decisions.

Subscribe to the newsletter

REGULATION AND LEGISLATION

Toronto Health Board to vote on decriminalisation of psychedelics.

Psychedelics may be the next drug reform frontier.

As ketamine clinics emerge in Seattle, so does debate about safety and regulations.

New Zealand legalises recreational drug testing.

Florida lawmaker introduces bill to decriminalise all drugs.

Partner with us